Position in CYTK
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$2,098,570
New position
Shares Held
24,634
first reported quarter
Ownership
0.018%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#220
of 477 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 16%
Shared 0%
None 84%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Phocas Financial Corp. holds $23,102,138 across 10 Biotechnology names. CYTK ranks #4 (9.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZVRA |
Zevra Therapeutics, Inc.
|
295,907 | $4,243,306 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
46,170 | $3,766,086 | |
| 3 | NRIX |
Nurix Therapeutics, Inc.
|
99,589 | $2,416,029 | |
| 4 | CYTK |
Cytokinetics Inc
This page
|
24,634 | $2,098,570 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
16,378 | $2,007,615 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
77,245 | $1,954,298 | |
| 7 | DNLI |
Denali Therapeutics Inc.
|
71,197 | $1,831,186 | |
| 8 | IDYA |
IDEAYA Biosciences, Inc.
|
48,822 | $1,819,595 |
All Filings in CYTK
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,098,570 | 24,634 | Shares | Sole | 2026-07-31 | |
| No filing history on record for this holder in this stock. | ||||||